Systematic review / meta-analysis / 2018
Oral and intramuscular vitamin B12 demonstrated similar effects on normalizing serum vitamin B12 levels based on low-quality evidence.
A Cochrane systematic review evaluated 3 RCTs (153 participants) comparing oral versus intramuscular (IM) vitamin B12 for deficiency, with follow-up lasting 3 to 4 months. In two trials using 1000 μg/day oral vitamin B12, there was no clinically relevant difference in vitamin B12 levels compared with IM administration, while one trial using 2000 μg/day reported a mean difference of 680 pg/mL favoring oral vitamin B12. Adverse events were reported in two trials (very low-quality evidence), with one noting no treatment-related adverse events and another reporting 2 of 30 oral participants leaving early due to adverse events. One trial found oral treatment had lower costs than IM (low-quality evidence), but no trials reported on clinical symptoms, quality of life, or acceptability.
- Study type
- Systematic review of randomized controlled trials
- Who was studied
- 153 participants with vitamin B12 deficiency across 3 RCTs (mean age 38.6 to 72 years)
- What was measured
- Serum vitamin B12 levels, clinical signs and symptoms, adverse events, treatment-associated costs
THE PAPER
Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency.
Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH. Cochrane Database Syst Rev, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.